Medicines Patent Pool Takes Novel Approach With Roche In Valcyte Deal
This article was originally published in PharmAsia News
Executive Summary
Roche and the Medicines Patent Pool have signed a five-year deal that will allow developing countries to achieve faster access to the Swiss company’s CMV drug, Valcyte for 90% less.